• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Pharmacomechanical thrombolysis does not lower risk of post-thrombotic syndrome: The ATTRACT trial

byJames RoebkerandDayton McMillan
December 8, 2017
in Cardiology, Emergency, Imaging and Intervention, Surgery
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients with proximal deep venous thrombosis (DVT) experience similar rates of post-thrombotic syndrome (PTS) when treated with pharmacomechanical catheter-directed thrombolysis (PCDT) plus anticoagulation versus anticoagulation alone.

2. Although treatment with PCDT and anticoagulation was associated with reduced severity of PTS compared to anticoagulation alone, no significant difference in quality of life was detected between the treatment groups.

Evidence Rating Level: 1 (Excellent)   

Study Rundown: Anticoagulation prevents thrombus extension in patients with DVT though it does not dissolve the original thrombus. PTS, consisting of leg swelling and chronic pain, occurs as a complication of DVT in a substantial number of patients. A recent randomized trial (CaVenT trial) demonstrated a reduction in PTS when catheter-directed thrombolysis (CDT) was added to anticoagulation for proximal DVTs. The Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT) trial was developed to assess whether PCDT, consisting of local fibrinolytic delivery and thrombus destabilization, reduced PTS in patients with a proximal DVT. The primary outcome, development of PTS between 6 and 24 months following treatment, was not significantly different in individuals treated with PCDT versus anticoagulation alone. Key secondary outcomes demonstrated no significant difference in quality of life measures between the two groups (despite a reduction in PTS severity with PCDT) and a higher risk of major bleeding in the PCDT group. This trial demonstrates little clinical benefit with the addition of PCDT in the treatment of proximal DVT.

This randomized, multicenter, blinded trial was larger and more generalizable than previous studies assessing the role of CDT for DVT management. Important limitations included a significant number of missed follow-up assessments for PTS and limited power to analyze treatment effects within subgroups. Follow-up to 2 years after randomization may also be a limitation, as the significance of CDT versus anticoagulation alone in the CaVenT trial increased at 5 years compared to 2 years.

Click to read the study in NEJM

Relevant Reading: Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliiofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial

RELATED REPORTS

Low-dose low-molecular weight heparin comparable to intermediate-dose for risk of venous thromboembolism in peripartum women

Thrombolysis harmful in acute ischemic strokes with large area of parenchymal hypoattenuation [Classics Series]

Intravenous tenecteplase non-inferior to alteplase for thrombolysis in acute ischemic stroke

In-Depth [randomized controlled trial]: This phase 3, multicenter, assessor-blinded trial enrolling patients between 2009 and 2014 randomized 692 adult patients with symptomatic proximal DVT (femoral, common femoral, or iliac vein) and without significant bleeding risks to PCDT plus anticoagulation (n = 336) or anticoagulation alone (n = 355). PCDT was performed through initial delivery of recombinant tissue plasminogen activator (rt-PA) followed by either balloon maceration, catheter aspiration, thrombectomy, percutaneous transluminal balloon venoplasty, stent placement, or a combination. The primary outcome, development of PTS between 6 and 24 months after treatment, was defined using a Villalta score of Âł5 or presence of a leg ulcer between 6- and 24-month follow-up. Severity of PTS was assessed using the Villalta scale. Quality of life scores were reported using standardized questionnaires. Patients were assessed following randomization at days 10 and 30, and months 6, 12, 18, and 24.

Thrombolysis was performed a median 1 day after randomization and mean degree of thrombus removal was 76%. PTS developed in 47% of patients (157/336) in the PCDT group and 48% (171/355) in the control group within 24-months (risk ratio [RR], 0.96; 95% confidence interval [CI], 0.82 to 1.11; p = 0.56). Moderate-to-severe PTS (Villalta score Âł10) occurred in 18% of patients in the PCDT group versus 24% in the control group (RR, 0.73; 95% CI, 0.54 to 0.98; p = 0.04). The severity of PTS was significantly lower in the PCDT at all time points (p < 0.01). There was no significant difference in the general quality of life (p = 0.37) or venous disease-specific quality of life (p = 0.08) scores between the treatment groups. Major bleeding within 10 days of treatment occurred in 6 patients (1.7%) in the PCDT group compared to 1 patient (0.3%) in the control group (p = 0.049).

Image: CC/Wiki

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: deep vein thrombosispost-thrombotic syndromethrombolysis
Previous Post

Value-based payment modifier program not associated with differences in performance program measures

Next Post

Recombinant viral vector treatment sustains endogenous factor IX activity in patients with hemophilia B

RelatedReports

Women electing abortion more likely to be victims of domestic violence
Chronic Disease

Low-dose low-molecular weight heparin comparable to intermediate-dose for risk of venous thromboembolism in peripartum women

November 29, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Neurology Classics

Thrombolysis harmful in acute ischemic strokes with large area of parenchymal hypoattenuation [Classics Series]

September 7, 2022
Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Chronic Disease

Intravenous tenecteplase non-inferior to alteplase for thrombolysis in acute ischemic stroke

July 27, 2022
Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Chronic Disease

Thrombectomy alone is inferior to thrombectomy plus alteplase for acute ischemic stroke

July 19, 2022
Next Post

Recombinant viral vector treatment sustains endogenous factor IX activity in patients with hemophilia B

Declining blood pressure in elderly associated with subcortical microinfarcts

Pediatric DKA associated with recent acute care visits

Individualized glycemic control for type 2 diabetes may save the U.S. billions annually

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
  • Homicide deaths are on the rise for children living in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options